Skip to content

Deep Learning in Retinoblastoma Detection and Monitoring.

Deep Learning Computer-aided Detection System for Retinoblastoma Detection and Monitoring.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05308043
Enrollment
200
Registered
2022-04-01
Start date
2020-03-01
Completion date
2022-10-01
Last updated
2022-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinoblastoma

Brief summary

Retinoblastoma is the most common eye cancer of childhood. Eye-preserving therapies require routine monitoring of retinoblastoma regression and recurrence to guide corresponding treatment. In the current study, we develop a deep learning algorism that can simultaneously identify retinoblastoma tumours on Retcam images and distinguish between active and inactive retinoblastoma tumours. This algorism will be validated through a prospectively collected dataset.

Detailed description

Retinoblastoma, the most common eye cancer of childhood, affects 1 in 15 000 to 1 in 18 000 live births. China has the second-largest number of patients with retinoblastoma in the world. Eye-preserving therapies have been used widely in China for approximately 15 years. Eye-preserving therapies require routine monitoring of retinoblastoma regression and recurrence to guide corresponding treatment. However, the major amount of qualified ophthalmologists are concentrated in several medical centres. Deep learning based on Retcam examination that can identify retinoblastoma will reduce screening accuracy of the local hospitals and reduce monitoring wordload. In the current study, a deep learning algorism was developed that can simultaneously identify retinoblastoma tumours on Retcam images and distinguish between active and inactive retinoblastoma tumours. This algorism will be validated through a prospectively collected dataset.

Interventions

DIAGNOSTIC_TESTDeep learning algorism

A deep learning algorism that was developed previous would be applied to identify retinoblastoma tumours on Retcam images and distinguish between active and inactive retinoblastoma tumours. The decision of two different senior ophthalmologists would be the gold standard.

Sponsors

Beijing Tongren Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
0 Years to 5 Years
Healthy volunteers
No

Inclusion criteria

* Retinoblastoma patients undergo standard medical management.

Exclusion criteria

* The operators identified images non-assessable for a correct diagnosis, due to reasons such as blur and defocus, and excluded them from further analysis.

Design outcomes

Primary

MeasureTime frameDescription
Diagnosis accurcy of deep learning algorism1 weekThe diagnosic accurcy of this deep learning algorism is the proportion of true positive and true negative in all evaluated cases

Countries

China

Contacts

Primary ContactWenbin Wei, MD
weiwenbintr@163.com010-58269523
Backup ContactRuiheng Zhang, MD
zhangruihengsy@outlook.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026